|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cahill MA, Jazayeri JA, Catalano SM,
Toyokuni S, Kovacevic Z and Richardson DR: The emerging role of
progesterone receptor membrane component 1 (PGRMC1) in cancer
biology. Biochim Biophys Acta. 1866:339–349. 2016.PubMed/NCBI
|
|
4
|
Zhu X, Han Y, Fang Z, Wu W, Ji M, Teng F,
Zhu W, Yang X, Jia X and Zhang C: Progesterone protects ovarian
cancer cells from cisplatin-induced inhibitory effects through
progesterone receptor membrane component 1/2 as well as AKT
signaling. Oncol Rep. 30:2488–2494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friel AM, Zhang L, Pru CA, Clark NC,
McCallum ML, Blok LJ, Shioda T, Peluso JJ, Rueda BR and Pru JK:
Progesterone receptor membrane component 1 deficiency attenuates
growth while promoting chemosensitivity of human endometrial
xenograft tumors. Cancer Lett. 356:434–442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clark NC, Friel AM, Pru CA, Zhang L,
Shioda T, Rueda BR, Peluso JJ and Pru JK: Progesterone receptor
membrane component 1 promotes survival of human breast cancer cells
and the growth of xenograft tumors. Cancer Biol Ther. 17:262–271.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mir SU, Ahmed IS, Arnold S and Craven RJ:
Elevated progesterone receptor membrane component 1/sigma-2
receptor levels in lung tumors and plasma from lung cancer
patients. Int J Cancer. 131:E1–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kabe Y, Nakane T, Koike I, Yamamoto T,
Sugiura Y, Harada E, Sugase K, Shimamura T, Ohmura M, Muraoka K, et
al: Haem-dependent dimerization of PGRMC1/sigma-2 receptor
facilitates cancer proliferation and chemoresistance. Nat Commun.
7:110302016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhuang L, Xu L, Wang P, Jiang Y, Yong P,
Zhang C, Zhang H, Meng Z and Yang P:
Na+/K+-ATPase α1 subunit, a novel therapeutic
target for hepatocellular carcinoma. Oncotarget. 6:28183–28193.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lefranc F and Kiss R: The sodium pump
alpha1 subunit as a potential target to combat apoptosis-resistant
glioblastomas. Neoplasia. 10:198–206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mathieu V, Pirker C, Martin de Lassalle E,
Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F,
Berger W and Kiss R: The sodium pump alpha1 sub-unit: A disease
progression-related target for metastatic melanoma treatment. J
Cell Mol Med. 13:3960–3972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mijatovic T, Roland I, Van Quaquebeke E,
Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V
and Kiss R: The alpha1 subunit of the sodium pump could represent a
novel target to combat non-small cell lung cancers. J Pathol.
212:170–179. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu IC, Chen YK, Wu CC, Cheng YJ, Chen WC,
Ko HJ, Liu YP, Chai CY, Lin HS, Wu DC and Wu MT: Overexpression of
ATPase Na+/+ transporting alpha 1 polypeptide, ATP1A1, correlates
with clinical diagnosis and progression of esophageal squamous cell
carcinoma. Oncotarget. 7:85244–85258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakai H, Suzuki T, Maeda M, Takahashi Y,
Horikawa N, Minamimura T, Tsukada K and Takeguchi N: Up-regulation
of Na+,K+-ATPase α3-isoform and
down-regulation of the α1-isoform in human colorectal cancer. FEBS
Lett. 563:151–154. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mobasheri A, Fox R, Evans I, Cullingham F,
Martín-Vasallo P and Foster CS: Epithelial Na, K-ATPase expression
is down-regulated in canine prostate cancer; a possible consequence
of metabolic transformation in the process of prostate malignancy.
Cancer Cell Int. 3:82003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Zhang Z, Xie JX, Li X, Tian J, Cai
T, Cui H, Ding H, Shapiro JI and Xie Z: Na/K-ATPase mimetic
pNaKtide peptide inhibits the growth of human cancer cells. J Biol
Chem. 286:32394–32403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang D, Xia X, Wang X, Zhang P, Lu W, Yu
Y, Deng S, Yang H, Zhu H, Xu N, et al: PGRMC1 is a novel potential
tumor biomarker of human renal cell carcinoma based on quantitative
proteomic and integrative biological assessments. PLoS One.
12:e01704532017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang D, Zhang P, Yang P, He Y, Wang X,
Yang Y, Zhu H, Xu N and Liang S: Downregulation of ATP1A1 promotes
cancer development in renal cell carcinoma. Clin Proteomics.
14:152017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng X, Li H, Kornaga EN, Dean M,
Lees-Miller SP, Riabowol K, Magliocco AM, Morris D, Watson PH,
Enwere EK, et al: Low Ki67/high ATM protein expression in malignant
tumors predicts favorable prognosis in a retrospective study of
early stage hormone receptor positive breast cancer. Oncotarget.
7:85798–85812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang S, Xu Z, Xu X, Zhao X, Huang C and
Wei Y: Quantitative proteomics for cancer biomarker discovery. Comb
Chem High Throughput Screen. 15:221–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun BS, Li Y, Zhang ZF, You J and Wang CL:
Osteopontin combined with CD44v6, a novel prognostic biomarker in
non-small cell lung cancer undergoing curative resection. Ann
Thorac Surg. 96:1943–1951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi
GM, Wu B, Dai Z, Liu YK, Tang ZY and Zhou J: Osteopontin combined
with CD44, a novel prognostic biomarker for patients with
hepatocellular carcinoma undergoing curative resection. Oncologist.
13:1155–1165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu DH, Wang TT, Ruan DY, Li X, Chen ZH,
Wen JY, Lin Q, Ma XK, Wu XY and Jia CC: Combination of ULK1 and
LC3B improve prognosis assessment of hepatocellular carcinoma.
Biomed Pharmacother. 97:195–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu C, Wei J, Tian X, Li Y and Li X:
Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma. Int
J Clin Exp Pathol. 8:12668–12677. 2015.PubMed/NCBI
|
|
25
|
Song YL, Yu R, Qiao XW, Bai CM, Lu CM,
Xiao Y, Zhong DR, Chen J, Zhao YP, Zhang TP, et al: Prognostic
relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine
tumors. Sci Rep. 7:22052017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zisman A, Pantuck AJ, Dorey F, Said JW,
Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA and
Belldegrun AS: Improved prognostication of renal cell carcinoma
using an integrated staging system. J Clin Oncol. 19:1649–1657.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang S, Xu Y, Shen G, Zhao X, Zhou J, Li
X, Gong F, Ling B, Fang L, Huang C and Wei Y: Gene expression and
methylation status of 14-3-3sigma in human renal carcinoma tissues.
IUBMB Life. 60:534–540. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin X, Liu Y, Liu J, Lu W, Liang Z, Zhang
D, Liu G, Zhu H, Xu N and Liang S: The overexpression of IQGAP1 and
β-catenin is associated with tumor progression in hepatocellular
carcinoma in vitro and in vivo. PLoS One. 10:e01337702015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen B, Zeng X, He Y, Wang X, Liang Z, Liu
J, Zhang P, Zhu H, Xu N and Liang S: STC2 promotes the
epithelial-mesenchymal transition of colorectal cancer cells
through AKT-ERK signaling pathways. Oncotarget. 7:71400–71416.
2016.PubMed/NCBI
|
|
30
|
Liang Z, Yang Y, He Y, Yang P, Wang X, He
G, Zhang P, Zhu H, Xu N, Zhao X and Liang S: SUMOylation of IQGAP1
promotes the development of colorectal cancer. Cancer Lett.
411:90–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong Z, Chen Y and Peng Y, Wang F, Yang Z,
Huang G, Chen Y, Yuan Z, Cao T and Peng Y: Concurrent CCR7
overexpression and RelB knockdown in immature dendritic cells
induces immune tolerance and improves skin-graft survival in a
murine model. Cell Physiol Biochem. 42:455–468. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salazar M, Lerma-Ortiz A, Hooks GM, Ashley
AK and Ashley RL: Progestin-mediated activation of MAPK and AKT in
nuclear progesterone receptor negative breast epithelial cells: The
role of membrane progesterone receptors. Gene. 591:6–13. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu J, Akkuratov EE, Bai Y, Gaskill CM,
Askari A and Liu L: Cell signaling associated with
Na+/K+-ATPase: activation of
phosphatidylinositide 3-kinase IA/Akt by ouabain is independent of
Src. Biochemistry. 52:9059–9067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang L, Wu J, Ling MT, Zhao L and Zhao
KN: The role of the PI3K/Akt/mTOR signalling pathway in human
cancers induced by infection with human papillomaviruses. Mol
Cancer. 14:872015. View Article : Google Scholar : PubMed/NCBI
|
